JP2011516613A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011516613A5 JP2011516613A5 JP2011505164A JP2011505164A JP2011516613A5 JP 2011516613 A5 JP2011516613 A5 JP 2011516613A5 JP 2011505164 A JP2011505164 A JP 2011505164A JP 2011505164 A JP2011505164 A JP 2011505164A JP 2011516613 A5 JP2011516613 A5 JP 2011516613A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- posaconazole
- infection
- pharmaceutical composition
- acetate succinate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4517708P | 2008-04-15 | 2008-04-15 | |
| US61/045,177 | 2008-04-15 | ||
| PCT/US2009/040653 WO2009129301A2 (en) | 2008-04-15 | 2009-04-15 | Oral pharmaceutical compositions in a molecular solid dispersion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011516613A JP2011516613A (ja) | 2011-05-26 |
| JP2011516613A5 true JP2011516613A5 (enExample) | 2013-03-21 |
Family
ID=41165581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011505164A Withdrawn JP2011516613A (ja) | 2008-04-15 | 2009-04-15 | 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110034478A1 (enExample) |
| EP (1) | EP2278957A2 (enExample) |
| JP (1) | JP2011516613A (enExample) |
| AU (1) | AU2009236290A1 (enExample) |
| CA (1) | CA2720851A1 (enExample) |
| WO (1) | WO2009129301A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI388324B (zh) * | 2008-04-15 | 2013-03-11 | Schering Corp | 含有泊沙康唑（ｐｏｓａｃｏｎａｚｏｌｅ）之高密度組合物及包含該組合物之調配物 |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| TW201010708A (en) * | 2008-06-02 | 2010-03-16 | Intervet Int Bv | Composition comprising an antibiotic and a corticosteroid |
| JP6336902B2 (ja) * | 2011-06-22 | 2018-06-06 | ビョーメ バイオサイエンシズ ピーブイティー．リミテッド | コンジュゲートベースの抗真菌性および抗菌性プロドラッグ |
| US9751957B2 (en) | 2012-02-15 | 2017-09-05 | Cydex Pharmaceuticals, Inc. | Manufacturing process for cyclodextrin derivatives |
| KR20160033795A (ko) | 2012-02-28 | 2016-03-28 | 사이덱스 파마슈티칼스, 인크. | 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법 |
| KR102112119B1 (ko) | 2012-10-22 | 2020-05-19 | 사이덱스 파마슈티칼스, 인크. | 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법 |
| US10646573B2 (en) | 2013-06-03 | 2020-05-12 | Shin-Etsu Chemical Co., Ltd. | Composition for hot melt extrusion and method for producing hot melt extrudate by using same |
| EP2837391B1 (en) | 2013-08-12 | 2017-05-10 | Shin-Etsu Chemical Co., Ltd. | Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate |
| JP6914188B2 (ja) | 2014-08-22 | 2021-08-04 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | 分画アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法 |
| JP6203702B2 (ja) | 2014-11-18 | 2017-09-27 | 信越化学工業株式会社 | ヒプロメロース酢酸エステルコハク酸エステルを用いたスプレードライ用溶液及び固体分散体の製造方法 |
| EP3415511A1 (en) | 2014-11-21 | 2018-12-19 | F2G Limited | Antifungal agents |
| EP3590505B1 (en) | 2015-08-08 | 2024-11-06 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Gastro-resistant formulation containing posaconazole |
| EP4424308A3 (en) | 2016-02-26 | 2024-12-04 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Gastro-resistant formulation containing posaconazole and a polymeric precipitation inhibitor |
| WO2017032908A1 (en) * | 2016-07-08 | 2017-03-02 | Synthon B.V. | Pharmaceutical composition comprising amorphous posaconazole |
| CN106265526A (zh) * | 2016-09-22 | 2017-01-04 | 山东大学 | 一种抗真菌药物泊沙康唑的固体分散体及制备方法与应用 |
| US10702520B1 (en) | 2019-01-29 | 2020-07-07 | Slayback Pharma Llc | Pharmaceutical compositions of posaconazole |
| US11819503B2 (en) | 2019-04-23 | 2023-11-21 | F2G Ltd | Method of treating coccidioides infection |
| WO2022034232A1 (en) | 2020-08-13 | 2022-02-17 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Gastro-resistant high-strength formulation containing posaconazole |
| EP4119128A1 (en) * | 2021-07-13 | 2023-01-18 | Dr. Falk Pharma Gmbh | Pharmaceutical composition for the oral administration of poorly soluble drugs comprising an amorphous solid dispersion |
| WO2023012378A1 (en) | 2021-11-25 | 2023-02-09 | Alfred E. Tiefenbacher (Gmbh Und Co. Kg) | Granules containing posaconazole |
| EP4091604B1 (en) | 2021-11-25 | 2024-04-03 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Granules containing posaconazole |
| CN117545470A (zh) * | 2023-09-18 | 2024-02-09 | 北京德立福瑞医药科技有限公司 | 泊沙康唑固体分散体及其制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4144346A (en) * | 1977-01-31 | 1979-03-13 | Janssen Pharmaceutica N.V. | Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles |
| SE7804231L (sv) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| US4978672A (en) * | 1986-03-07 | 1990-12-18 | Ciba-Geigy Corporation | Alpha-heterocyclc substituted tolunitriles |
| US4916134A (en) * | 1987-03-25 | 1990-04-10 | Janssen Pharmacuetica N.V. | 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones |
| US5278175A (en) * | 1990-02-02 | 1994-01-11 | Pfizer Inc. | Triazole antifungal agents |
| US5703079A (en) * | 1993-12-21 | 1997-12-30 | Schering Corporation | Tetrahydrofuran antifungals |
| US5661151A (en) * | 1993-12-21 | 1997-08-26 | Schering Corporation | Tetrahydrofuran antifungals |
| NZ270418A (en) * | 1994-02-07 | 1997-09-22 | Eisai Co Ltd | Polycyclic triazole & imidazole derivatives, antifungal compositions |
| US5790957A (en) * | 1995-09-12 | 1998-08-04 | Nokia Mobile Phones Ltd. | Speech recall in cellular telephone |
| US5834472A (en) * | 1996-05-24 | 1998-11-10 | Schering Corporation | Antifungal composition with enhanced bioavailability |
| US5846971A (en) * | 1996-06-28 | 1998-12-08 | Schering Corporation | Oral antifungal composition |
| US5972381A (en) * | 1996-06-28 | 1999-10-26 | Schering Corporation | Solid solution of an antifungal agent with enhanced bioavailability |
| US6713481B1 (en) * | 1997-10-17 | 2004-03-30 | David R. Andrews | Crystalline antifungal polymorph |
| NZ507760A (en) * | 1998-03-26 | 2002-10-25 | Japan Tobacco Inc | Amide derivatives and nociceptin antagonists |
| PT1239831E (pt) * | 1999-12-23 | 2013-01-23 | Mayne Pharma International Pty Ltd | Composições farmacêuticas melhoradas para fármacos fracamente solúveis |
| US20010053791A1 (en) * | 2000-03-16 | 2001-12-20 | Babcock Walter C. | Glycogen phosphorylase inhibitor |
| GB0104752D0 (en) * | 2001-02-27 | 2001-04-18 | Astrazeneca Ab | Pharmaceutical compositions |
| EP2090165A3 (en) * | 2001-04-03 | 2012-03-28 | Schering Corporation | Antifungal composition with enhanced bioavailability |
| US20060160823A1 (en) * | 2004-05-28 | 2006-07-20 | Leonore Witchey-Lakshmanan | Particulate-stabilized injectable pharmaceutical compositions of Posaconazole |
| WO2006034080A2 (en) * | 2004-09-17 | 2006-03-30 | Nektar Therapeutics | Formulation comprising itraconazole |
| US20060275230A1 (en) * | 2004-12-10 | 2006-12-07 | Frank Kochinke | Compositions and methods for treating conditions of the nail unit |
| JP2009514884A (ja) * | 2005-11-04 | 2009-04-09 | イーストマン ケミカル カンパニー | 難溶性医薬活性剤の投与のためのカルボキシアルキルセルロースエステル |
| TWI388324B (zh) * | 2008-04-15 | 2013-03-11 | Schering Corp | 含有泊沙康唑（ｐｏｓａｃｏｎａｚｏｌｅ）之高密度組合物及包含該組合物之調配物 |
-
2009
- 2009-04-15 WO PCT/US2009/040653 patent/WO2009129301A2/en not_active Ceased
- 2009-04-15 EP EP09732492A patent/EP2278957A2/en not_active Withdrawn
- 2009-04-15 US US12/937,881 patent/US20110034478A1/en not_active Abandoned
- 2009-04-15 CA CA2720851A patent/CA2720851A1/en not_active Abandoned
- 2009-04-15 AU AU2009236290A patent/AU2009236290A1/en not_active Abandoned
- 2009-04-15 JP JP2011505164A patent/JP2011516613A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011516613A5 (enExample) | ||
| de Lacerda Coriolano et al. | Antibacterial and antibiofilm potential of silver nanoparticles against antibiotic-sensitive and multidrug-resistant Pseudomonas aeruginosa strains | |
| Huang et al. | Self-assemblies based on traditional medicine berberine and cinnamic acid for adhesion-induced inhibition multidrug-resistant Staphylococcus aureus | |
| Macedo et al. | Usnic acid: From an ancient lichen derivative to promising biological and nanotechnology applications | |
| Ansari et al. | Recent advances in the therapeutic applications of selenium nanoparticles | |
| Das et al. | Silymarin nanoparticle prevents paracetamol-induced hepatotoxicity | |
| Ng et al. | In vitro evaluation of curcumin‐encapsulated chitosan nanoparticles against feline infectious peritonitis virus and pharmacokinetics study in cats | |
| Michaelis et al. | Effects of flavonoid-induced oxidative stress on anti-H5N1 influenza a virus activity exerted by baicalein and biochanin A | |
| CL2010001358A1 (es) | Composicion farmaceutica que comprende un vehiculo farmaceuticamente aceptable y una combinacion de dos dosis de pramipexol y rasagilina, en donde la combinacion a dosis fija contiene desde 0,06 a menos de 1,5 mg de pramipexol y desde 0,05 mg a menos de 1,0 mg de rasagilina. | |
| CL2009000902A1 (es) | Composicion que comprende posaconazol disuelto o disperso molecularmente en un polimero derivado de hidroxipropilcelulosa; formulacion farmaceutica que comprende a la composion; un proceso para preparar a la composicion mediante fusioextrusion; y su uso para tratar una infeccion micotica. | |
| Lou et al. | Oridonin nanosuspension enhances anti-tumor efficacy in SMMC-7721 cells and H22 tumor bearing mice | |
| Do et al. | Advances in silver nanoparticles: unraveling biological activities, mechanisms of action, and toxicity | |
| Suresh et al. | Therapeutic potential of curcumin in ARDS and COVID‐19 | |
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| Shin et al. | Comparison of anti-influenza virus activity and pharmacokinetics of oseltamivir free base and oseltamivir phosphate | |
| Yoosefian et al. | Silver nanoparticle-based drug delivery systems in the fight against COVID-19: enhancing efficacy, reducing toxicity and improving drug bioavailability | |
| Wollina | Peat: a natural source for dermatocosmetics and dermatotherapeutics | |
| Rai et al. | Harnessing bioactive nanocurcumin and curcumin nanocomposites to combat microbial pathogens: a comprehensive review | |
| Hashempur et al. | Topical Delivery Systems for Plant‐Derived Antimicrobial Agents: A Review of Current Advances | |
| Tavakoli et al. | Nanostructures for the Prevention, Diagnosis, and Treatment of COVID‐19: A Review | |
| TWI492751B (zh) | 柴胡皂苷製備之醫藥組合物、其用途及其製備方法 | |
| Sotoudeheian et al. | Targeting SIRT1 by Scopoletin to Inhibit XBB. 1.5 COVID-19 Life Cycle | |
| A Marathe et al. | Herbal cocktail as anti-infective: promising therapeutic for the treatment of viral diseases | |
| Patel et al. | Potential of Nanotechnology-based Formulations in Combating Pulmonary Infectious Diseases: A Current Scenario | |
| Vartak et al. | Nanomedicine for the Treatment of Vaginal Candidiasis |